Filgotinib: A Clinical Pharmacology Review.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
accepted:
10
04
2022
pubmed:
1
6
2022
medline:
8
7
2022
entrez:
31
5
2022
Statut:
ppublish
Résumé
Filgotinib (GS-6034, formerly GLPG0634; Jyseleca
Identifiants
pubmed: 35637376
doi: 10.1007/s40262-022-01129-y
pii: 10.1007/s40262-022-01129-y
pmc: PMC9249714
doi:
Substances chimiques
GLPG0634
0
Janus Kinase Inhibitors
0
Pyridines
0
Triazoles
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
819-832Informations de copyright
© 2022. The Author(s).
Références
Isomäki P, Junttila I, Vidqvist KL, Korpela M, Silvennoinen O. The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels. Rheumatology (Oxford). 2015;54:1103–13. https://doi.org/10.1093/rheumatology/keu430 .
doi: 10.1093/rheumatology/keu430
Neurath M. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:688. https://doi.org/10.1038/nrgastro.2017.138 .
doi: 10.1038/nrgastro.2017.138
pubmed: 29018274
Schwartz DM, Bonelli M, Gadina M, O’Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36. https://doi.org/10.1038/nrrheum.2015.167 .
doi: 10.1038/nrrheum.2015.167
pubmed: 26633291
Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005;32:1650–3.
pubmed: 16142855
Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521–46. https://doi.org/10.1007/s40265-017-0701-9 .
doi: 10.1007/s40265-017-0701-9
pubmed: 28255960
pmcid: 7102286
Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13:693–703. https://doi.org/10.1080/1744666X.2017.1291342 .
doi: 10.1080/1744666X.2017.1291342
pubmed: 28164724
Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–75. https://doi.org/10.1016/S0140-6736(16)32537-5 .
doi: 10.1016/S0140-6736(16)32537-5
pubmed: 27988142
O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii111–5. https://doi.org/10.1136/annrheumdis-2012-202576 .
doi: 10.1136/annrheumdis-2012-202576
Sandborn WJ, Feagan BG, De Hertogh G, Chen G, French DF, Huntzicker EG, et al. Filgotinib (GLPG0634, GS-6034), a JAK-1 selective inhibitor, significantly reduces gut tissue PSTAT3 in Crohn’s disease patients. Gastroenterology. 2017;152(Suppl 1):S602.
doi: 10.1016/S0016-5085(17)32149-2
Gilead Sciences. Jyseleca summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf . Accessed 9 Oct 2021.
Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signaling by filgotinib, upadacitinib, tofacitinib, and baricitinib. Ann Rheum Dis. 2021;80:865–75. https://doi.org/10.1136/annrheumdis-2020-219012 .
doi: 10.1136/annrheumdis-2020-219012
pubmed: 33741556
Galien R, Vayssiere B, De Vos S, Auberval M, Vandeghinste N, Dupont S, et al. Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy volunteers and rheumatoid arthritis patients. Arthritis Rheum. 2013;65(10 Suppl):S209–10.
Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of Phase IIB dose selection. Clin Pharmacokinet. 2015;54:859–74. https://doi.org/10.1007/s40262-015-0240-z .
doi: 10.1007/s40262-015-0240-z
pubmed: 25681059
pmcid: 4513223
Genovese MC, Kalunian K, Gottenberg J-E, Mozaffarian N, Bartok B, Matzkies F, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322:315–25. https://doi.org/10.1001/jama.2019.9055 .
doi: 10.1001/jama.2019.9055
pubmed: 31334793
pmcid: 6652745
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80:848–58. https://doi.org/10.1136/annrheumdis-2020-219214 .
doi: 10.1136/annrheumdis-2020-219214
pubmed: 33504485
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80:727–38. https://doi.org/10.1136/annrheumdis-2020-219213 .
doi: 10.1136/annrheumdis-2020-219213
pubmed: 33452004
Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372–84. https://doi.org/10.1016/S0140-6736(21)00666-8 .
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Assessment report: Jyseleca. EMA/424374/2020. Available from: https://www.ema.europa.eu/en/documents/assessment-report/jyseleca-epar-public-assessment-report_en.pdf . Accessed 4 Feb 2021.
Menet CJ, Fletcher SR, Van Lommen G, Geney R, Blanc J, Smits K, et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J Med Chem. 2014;57:9323–42. https://doi.org/10.1021/jm501262q .
doi: 10.1021/jm501262q
pubmed: 25369270
Anderson K, Xin Y, Zheng H, Yun C, Kwan E, Qin A, et al. Filgotinib, a JAK1 inhibitor, has no effect on QT interval in healthy subjects. Clin Pharmacol Drug Dev. 2020;9:32–40. https://doi.org/10.1002/cpdd.755 .
doi: 10.1002/cpdd.755
pubmed: 31797578
Anderson K, Zheng H, Kotecha M, Cuvin J, Scott B, Sharma S, et al. The relative bioavailability and effects of food and acid-reducing agents on filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev. 2019;8:585–94. https://doi.org/10.1002/cpdd.659 .
doi: 10.1002/cpdd.659
pubmed: 30768860
Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191:3568–77. https://doi.org/10.4049/jimmunol.1201348 .
doi: 10.4049/jimmunol.1201348
pubmed: 24006460
Anderson K, Zheng H, Medzihradsky O, Yizhao L, Qin A, Kearney B, et al. Pharmacokinetics and short-term safety of filgotinib, a selective Janus kinase 1 inhibitor, in subjects with moderate hepatic impairment. Ann Rheum Dis. 2019;78(Suppl 2):331.
Namour F, Desrivot J, Van der Aa A, Harrison P, Tasset C, van't Klooster G. Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions. Drug Metab Lett. 2016;10:38–48. https://doi.org/10.2174/1872312810666151223103353 .
doi: 10.2174/1872312810666151223103353
pubmed: 26693854
Di L. The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr Drug Metab. 2019;20:91–102. https://doi.org/10.2174/1389200219666180821094502 .
doi: 10.2174/1389200219666180821094502
pubmed: 30129408
Namour F, Fagard L, Van der Aa A, Harrison P, Xin Y, Tasset C. Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. Br J Clin Pharmacol. 2018;84:2779–89. https://doi.org/10.1111/bcp.13726 .
doi: 10.1111/bcp.13726
pubmed: 30088677
pmcid: 6256002
Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, et al. Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs. J Rheumatol. 2021;48:1230–8. https://doi.org/10.3899/jrheum.201183 .
doi: 10.3899/jrheum.201183
pubmed: 33526618
Tanaka Y, Kavanaugh A, Wicklund J, McInnes IB. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: an overview from clinical trials. Mod Rheumatol. 2022;32:1–11. https://doi.org/10.1080/14397595.2021.1902617 .
doi: 10.1080/14397595.2021.1902617
pubmed: 34918136
Namour F, Vayssiere B, Galien R, Fagard L, Van der Aa A, Harrison P, et al. Filgotinib (GLPG0634), a selective JAK1 inhibitor, shows similar PK and PD profiles in Japanese and Caucasian healthy volunteers. Ann Rheum Dis. 2015;74(Suppl 2):1063–4.
doi: 10.1136/annrheumdis-2015-eular.4457
Imai T, Taketani M, Shii M, Hosokawa M, Chiba K. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos. 2006;34:1734–41. https://doi.org/10.1124/dmd.106.009381 .
doi: 10.1124/dmd.106.009381
pubmed: 16837570
Hsueh C-H, Anderson K, Shen G, Yun C, Qin A, Othman AA. Evaluation of the potential drug interactions mediated through P-gp, OCT2 and MATE1/2K with filgotinib in healthy subjects. Clin Trans Sci. 2022;15:361–70. https://doi.org/10.1111/cts.13152 .
doi: 10.1111/cts.13152
Anderson K, Nelson CH, Gong Q, Alani M, Tarnowski T, Othman AA. Assessment of the effect of filgotinib on the pharmacokinetics of atorvastatin, pravastatin, and rosuvastatin in healthy adult participants. Clin Pharmacol Drug Dev. 2022;11:235–45. https://doi.org/10.1002/cpdd.1015 .
Barbosa ACS, Feng Y, Yu C, Huang M, Xie W. Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases. Expert Opin Drug Metab Toxicol. 2019;15:329–39. https://doi.org/10.1080/17425255.2019.1588884 .
doi: 10.1080/17425255.2019.1588884
pubmed: 30822161
pmcid: 6428602
Tong MH, Jiang H, Liu P, Lawson JA, Brass LF, Song WC. Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med. 2005;11:153–9. https://doi.org/10.1038/nm1184 .
doi: 10.1038/nm1184
pubmed: 15685171
Begley R, Anderson K, Watkins TR, Weng W, Ampaw L, Qin A, et al. Lack of drug-drug interaction between filgotinib, a selective JAK1 inhibitor, and oral hormonal contraceptives levonorgestrel/ethinyl estradiol in healthy volunteers. Clin Pharmacol Drug Dev. 2020;10:376–83. https://doi.org/10.1002/cpdd.870 .
doi: 10.1002/cpdd.870
pubmed: 32989920
Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76:1009–19. https://doi.org/10.1136/annrheumdis-2016-210105 .
doi: 10.1136/annrheumdis-2016-210105
pubmed: 27993828
Westhovens R, Taylor PC, Alten R, Pavlova D, Enríquez-Sosa F, Mazur M, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76:998–1008. https://doi.org/10.1136/annrheumdis-2016-210104 .
doi: 10.1136/annrheumdis-2016-210104
pubmed: 27993829